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ABSTRACT
Objectives To compare the effectiveness and safety of 
naproxen and low- dose colchicine for treating gout flares 
in primary care.
Methods This was a multicentre open- label randomised 
trial. adults with a gout flare recruited from 100 general 
practices were randomised equally to naproxen 750 mg 
immediately then 250 mg every 8 hours for 7 days or 
low- dose colchicine 500 mcg three times per day for 4 
days. The primary outcome was change in worst pain 
intensity in the last 24 hours (0–10 numeric Rating 
scale) from baseline measured daily over the first 7 days: 
mean change from baseline was compared between 
groups over days 1–7 by intention to treat.
Results Between 29 January 2014 and 31 December 
2015, we recruited 399 participants (naproxen n=200, 
colchicine n=199), of whom 349 (87.5%) completed 
primary outcome data at day 7. There was no significant 
between- group difference in average pain- change scores 
over days 1–7 (colchicine vs naproxen: mean difference 
−0.18; 95% Ci −0.53 to 0.17; p=0.32). During days 
1–7, diarrhoea (45.9% vs 20.0%; OR 3.31; 2.01 to 
5.44) and headache (20.5% vs 10.7%; 1.92; 1.03 to 
3.55) were more common in the colchicine group than 
the naproxen group but constipation was less common 
(4.8% vs 19.3%; 0.24; 0.11 to 0.54).
Conclusion We found no difference in pain intensity 
over 7 days between people with a gout flare 
randomised to either naproxen or low- dose colchicine. 
naproxen caused fewer side effects supporting naproxen 
as first- line treatment for gout flares in primary care in 
the absence of contraindications.
Trial registration number isRCTn (69836939),  
clinicaltrials. gov (nCT01994226), eudraCT (2013-
001354-95).
InTROduCTIOn
Gout affects 2.5% of adults in the UK and 3.8% in 
the USA.1 2 It causes sudden flares of excruciating 
joint pain and swelling, which are treated with non- 
steroidal anti- inflammatory drugs (NSAIDs), low- 
dose colchicine or corticosteroids.3–5
Numerous randomised trials demonstrate that 
NSAIDs treat gout flares effectively.6 7 However, 
side effects are frequent and can be life- threatening. 
NSAIDs are commonly used in all age groups: 
three- quarters of NSAID prescriptions for gout 
flares in the UK in 2001–2004 were for diclofenac 
or indomethacin,8 two of the most toxic NSAIDs.9 
Naproxen is associated with lower vascular risk 
than other NSAIDs and is as effective as oral pred-
nisolone for gout flares.9 10
High- dose colchicine is effective but commonly 
causes gastrointestinal side effects.6 8 11–13 Lower 
doses are as effective but better tolerated.14 The 
recommended ‘low- dose’ regimen in the UK is 500 
mcg two to four times per day,3 15 however, the 
effectiveness and tolerability of this dose have never 
been evaluated. A direct comparison of an NSAID 
and low- dose colchicine is needed to inform choice 
for patients and practitioners.
The Colchicine Or Naproxen Treatment for 
ACute gouT (CONTACT) trial aimed to compare 
the clinical effectiveness of naproxen and low- 
dose colchicine at reducing pain from gout flares 
in primary care, their side- effect profiles and 
cost- effectiveness.
Key messages
What is already known about this subject?
 ► Non- steroidal anti- inflammatory drugs (NSAIDs) 
are effective treatments for gout flare, but side 
effects are frequent.
 ► Lower doses of colchicine are as effective as 
and better tolerated than high doses but have 
never been compared directly with an NSAID.
What does this study add?
 ► There was no difference between the effect of 
naproxen and low- dose colchicine on pain from 
gout flare.
 ► Naproxen was associated with fewer side 
effects, lower use of other analgesics and was 
cost- effective.
How might this impact on clinical practice or 
future developments?
 ► In the absence of contraindications, naproxen 
should be used ahead of low- dose colchicine in 
primary care on the grounds of effectiveness, 
safety and cost.
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MeTHOdS
Study design
This was a randomised, multicentre, open- label, pragmatic clin-
ical trial. The trial protocol is available at https://www. keele. ac. 
uk/ pchs/ research/ infl amma tory cond itions/ contact/
Participants
We recruited participants from 100 general practices across 
England. Registered patients who had consulted for gout in 
the preceding 2 years were mailed trial information before trial 
commencement and then 3 monthly inviting them to consult 
their general practitioner (GP) about the trial if they experienced 
a gout flare. Patients experiencing their first- ever flare were 
provided with trial information when they consulted.
Eligibility was assessed by the GP during a routine consulta-
tion. Participants were aged 18 years and over, consulting for 
a current gout flare, and had capacity and willingness to give 
consent and complete trial documentation. A clinical diagnosis 
of gout was made by the GP without joint aspiration, blood tests, 
imaging or diagnostic criteria. Exclusion criteria were unstable 
medical conditions (eg, ischaemic heart disease, impaired liver 
function); known stage 4/5 chronic kidney disease (estimated 
glomerular filtration rate/creatinine clearance <30 mL/min); 
recent surgery or gastrointestinal bleed; history of gastric ulcer; 
current anticoagulant use; allergy to aspirin or NSAID; previous 
inability to tolerate naproxen or low- dose colchicine; other 
contraindication to either study drug described in the Summary 
of Product Characteristics; prescription of naproxen or colchi-
cine in the previous 24 hours; pregnancy or lactation; potentially 
vulnerable patients; and participation in the CONTACT trial 
during a previous gout flare or involvement in another clinical 
trial in the last 90 days or other research within the last 30 days. 
Written informed consent was obtained prior to participation.
Randomisation, masking and interventions
Participants were randomly allocated 1:1 using simple randomi-
sation to either:
1. Single initial dose of oral naproxen 750 mg (three 250 mg 
tablets) followed by 250 mg (one tablet) every 8 hours for up 
to 7 days. Co- prescription of a proton- pump inhibitor was at 
the GP’s discretion.
2. Oral colchicine 500 mcg (one tablet) every 8 hours for 4 
days. Participants prescribed a statin were advised to omit 
the statin during colchicine treatment.
Randomisation was undertaken by the healthcare professional 
using web- access to a secure remote allocation system or, if this 
could not be accessed, a telephone randomisation service. Clini-
cians did not know which treatment a participant would receive 
prior to randomisation ensuring allocation concealment.
The GP prescribed the allocated medication. Participants and 
treating clinicians were aware of treatment allocation. Partici-
pants received a drug- specific advice leaflet that included advice 
about non- pharmacological treatment (rest, application of ice) 
and were offered reimbursement for prescription charges.
data collection
Baseline data were collected by self- complete questionnaire 
prior to randomisation. Outcome measures were collected by 
self- complete daily diary (days 1–7) and a questionnaire at week 
4. On study entry, participants chose between paper (postal) or 
web- based (e- mail invitation) follow- up. Reminders were sent 
during week 1 (postcard or daily e- mail reminders). If diary data 
were not received by day 10, a blinded research nurse telephoned 
participants to capture key outcome data. Non- responders to 
the 4- week questionnaire were sent postal/e- mail reminders at 2 
weeks and 4 weeks after initial mailing. Non- responders to the 
second reminder were telephoned by the research nurse and, if 
not successfully contacted, mailed a brief questionnaire.
Participants provided consent for review of their medical 
records over the 4- week study period to capture serious adverse 
events including hospitalisations and deaths.
Outcomes
On days 0–7 and at week 4, participants rated the intensity of 
the worst pain experienced in the last 24 hours using a validated 
0–10 Numeric Rating Scale (NRS).16 The primary outcome 
was change in pain intensity from baseline measured over 
the first 7 days. Secondary outcomes were time- to- treatment 
effect; complete pain resolution (reporting 0 or 1 on NRS); 
self- reported side effects (nausea, vomiting, headache, skin 
rash, dyspepsia, abdominal pain, constipation and diarrhoea); 
patient global assessment of treatment response (completely 
better/much better/somewhat better/about the same/some-
what worse/much worse); use of corticosteroids, paracetamol, 
NSAIDs or opiates for gout pain; treatment adherence; relapse/
recurrent gout flare; quality of life (EQ- 5D- 5L)17; attendance 
at GP, emergency department or primary care out- of- hours 
service; and absence from work/education. Worst pain inten-
sity in the last 24 hours, side effects, medication use for gout 
pain and treatment adherence were assessed daily during days 
1–7 and at week 4. EQ- 5D- 5L and patient global assessment 
of treatment response were assessed at day 7 and week 4. 
Relapse/recurrent gout flare, re- attendance and work absence 
were assessed at week 4.
Sample size
We aimed to assess the superiority of naproxen or colchicine 
(two- tailed hypothesis testing). A sample size of 200 partici-
pants per arm was required to detect a small standardised effect 
size (ES) of 0.3, allowing for the repeated measures structure 
(assumed autocorrelation 0.6), 20% loss to follow- up, 1:1 allo-
cation ratio, 90% power and two- sided type 1 error of 0.05.18
Statistical analysis
The main analysis was by intention- to- treat (ITT) evaluating 
participants as per allocation assignment. Mean change in 
worst pain intensity in the last 24 hours from baseline to each 
follow- up time point was calculated for each group. Anal-
ysis of the primary outcome was by linear mixed model with 
autoregressive covariance for repeated measures.19 Between- 
group mean differences for each day (and at week four) were 
derived from the group×time interaction within the model. 
Standardised between- group mean differences for pain were 
expressed as the estimated mean differences relative to the 
baseline SD of pain scores (ES).18 Analyses of primary and 
secondary outcomes were performed before and after adjust-
ment for baseline pain score, age and gender.
The proportion of participants reporting complete pain 
resolution and time- to- first resolution of pain was compared 
between groups through χ2 and Mann- Whitney U tests, respec-
tively. Stepped per- protocol evaluations of between- group differ-
ence in the primary outcome were undertaken by excluding: (1) 
protocol violators related to treatment and eligibility; (2) those 
who did not take their designated treatment at any point and (3) 
those who did not take the full treatment course (naproxen <7 
days, colchicine <4 days).
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Figure 1 Participant flow. CTU, Clinical Trials Unit. ITT, intention- to- treat.
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Table 1 Baseline characteristics
Key characteristics Categories naproxen Colchicine
Age: mean (SD) – 58.7 (14.4) 60.0 (13.4)
Male, n (%) 173 (86.5) 174 (87.4)
Pain NRS (0–10), 
mean (SD)
– 7.1 (2.1) 6.9 (2.2)
Missing data 7 5
First instance of gout, 
n (%)
– 35 (17.9) 51 (26.2)
Missing data 4 4
Age when diagnosed, 
mean (SD)
52.1 (15.2) 53.4 (14.6)
Missing data 6 7
Body part affected, 
n (%)
First MTPJ 142 (72.4) 135 (69.2)
Other foot joints 58 (29.6) 48 (24.6)
Other lower limb 46 (23.5) 47 (24.1)
Upper limb 23 (11.7) 31 (15.9)
Missing data 4 4
Number of body parts 
affected, n (%)
1 139 (70.9) 145 (74.3)
2 34 (17.3) 27 (13.8)
3 13 (6.6) 9 (4.6)
4 6 (3.1) 13 (6.7)
≥5 4 (2.0) 1 (0.5)
Missing data 4 4
EQ- 5D- 5L, mean (SD) – 0.665 (0.210) 0.666 (0.225)
Missing data 8 6
MTPJ, metatarsophalangeal joint; NRS, Numeric Rating Scale.
Binary or ordinal logistic models were used to estimate ORs 
for between- group comparisons of secondary outcomes: patient 
global assessment of treatment response; relapse/recurrent gout 
flare; re- attendance; time off work because of gout; use of other 
medications for gout pain; and side effects, based on complete 
data and multiple imputation (MI) using chained equations 
based on 50 imputed data sets including treatment and sociode-
mographic variables as predictors. Separate MI evaluations were 
undertaken to maintain reasonable cases- to- variables ratio >520: 
imputed variables comprised (i) primary/secondary health vari-
ables (excluding side effects) across baseline and follow- up and 
health utilisation at week 4 and (ii) key health variables (ie, pain, 
global response, EQ- 5D- 5L) plus days 1–7 and week 4 medi-
cation and side- effect variables.21 Number needed to treatment 
harm was estimated for side effects as the reciprocal of the abso-
lute risk difference.22
In a sensitivity analysis, between- group differences in the 
primary outcome based on more inclusive baseline covariates 
including adjustment for first episode, age at first flare, location 
of gout, EQ- 5D- 5L, index of deprivation (fixed factors) and 
GP practice (random factor) were examined via MI evaluation 
(imputation data set (i) above).
Analysis was performed when all participants had completed 
follow- up; no interim analysis was performed. Primary and 
secondary outcomes (except per- protocol and health economic 
evaluations) were analysed blind to treatment allocation. The 
primary endpoint analysis was independently analysed by two 
statisticians. All analyses were carried out using SPSS V.21.0 and 
STATA V.14.0.
Health economics
An incremental cost- utility analysis from a National Health 
Service (NHS)/personal social services perspective was under-
taken. Unit costs (2015/2016 prices) from standard UK sources 
were applied to resource use data. EQ- 5D- 5L index scores were 
generated using the UK value set to calculate QALYs over the 
4- week follow- up period.23
Resource use, costs and EQ- 5D- 5L scores were summarised 
using descriptive statistics. Missing EQ- 5D- 5L scores and 
costs were imputed using MI. QALYs were calculated for each 
participant using EQ- 5D- 5L responses. A regression approach 
controlled for imbalances in baseline EQ- 5D- 5L scores between 
treatment arms. Mean costs were estimated by treatment arm 
and the difference in mean costs (95% CI) calculated using non- 
parametric bootstrapping.24
Incremental cost- effectiveness ratios were estimated by 
dividing the mean cost difference between arms by the difference 
in mean QALYs. Five thousand pairs of mean cost and QALY 
differences were estimated by non- parametric bootstrapping 
and presented on a cost- effectiveness plane. Cost- effectiveness 
acceptability curves were plotted to determine the probability 
that naproxen was cost- effective.25
The human capital approach was used to estimate productivity 
costs from employment status and days off work due to health. 
The average wage for each respondent was identified using UK 
Standard Occupational Classification coding and annual earn-
ings data.26
Patient and public involvement
This trial was developed with research users with gout who 
provided feedback on the proposed recruitment and consent 
processes and choice of trial outcomes. Two patient representa-
tives sat on the independent trial steering committee, playing a 
full part in monitoring trial progress and conduct, and provided 
advice on the design of questionnaires and Participant Informa-
tion Leaflets.
ReSulTS
Between 29 January 2014 and 31 December 2015, 5155 patients 
were mailed. Three- hundred and ninety- nine participants were 
randomised: 200 to receive naproxen and 199 to receive colchi-
cine (figure 1). Groups were similar at baseline although more 
people allocated to colchicine reported experiencing their first- 
ever gout flare (table 1, online supplementary table 1). Primary 
outcome data were collected for 86.0% in the naproxen group at 
day 7 and 86.5% at 4 weeks and 88.9% in the colchicine group 
at both day 7 and 4 weeks (figure 1).
There were 30 protocol violations (8% of participants) relating 
to treatment or eligibility (naproxen n=14, colchicine n=16). 
Of those returning diary data, 99% (163/164) reported taking 
the allocated treatment at least once and 75% (125) taking it on 
each day of the course in the naproxen group compared with 
98% (168/171) and 85% (144), respectively, for colchicine.
Within- group improvements in the primary outcome were 
seen in both groups over days 1–7 (figure 2). There was no 
significant between- group difference in mean change in worst 
pain intensity over days 1–7 (colchicine vs naproxen: adjusted 
mean difference −0.18; 95% CI −0.53 to 0.17; p=0.32; ES 
0.09). Unadjusted estimates and MI evaluation with extended 
covariate adjustment were similar. There was a small between- 
group difference favouring naproxen on day 2 only.
Per- protocol analysis (1) showed comparable between- group 
mean differences to the ITT evaluation (online supplementary 
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Figure 2 Comparison of pain scores (primary outcome measure) at follow- up (intention- to- treat analysis).
table 2). Per- protocol analyses (2) and (3) showed similar 
between- group differences to the ITT analysis overall and on 
days 1–6 but found small significant differences favouring 
naproxen at week 4.
There were no between- group differences in complete pain 
resolution or patient global assessment of treatment response 
at any time- point (table 2, online supplementary table 3). At 
week 4, there were no between- group differences in proportions 
reporting a relapse/recurrent gout flare; consulting a GP, practice 
nurse or emergency department; or time off work.
More participants in the colchicine group used paracetamol 
or codeine for gout during days 1–7 than in the naproxen group 
(table 3). At week 4, ibuprofen use was more common in the 
colchicine group on complete case analysis but not in the MI 
data set.
There were three serious adverse events, none related to trial 
interventions, and no deaths. Two participants who received 
naproxen were hospitalised: one for non- cardiac chest pain and 
one for hospital- acquired pneumonia following a transcath-
eter aortic valve implantation. One participant who received 
colchicine was hospitalised with osteomyelitis. During days 
1–7, self- reported diarrhoea and headache were more common 
with colchicine than naproxen, whereas constipation was less 
common with colchicine (table 4). Diarrhoea peaked on day 4 in 
the colchicine group and constipation on day 3 in the naproxen 
group (online supplementary table 4). Both reduced consider-
ably during weeks 2–4.
Naproxen was slightly less costly and more effective than 
colchicine (online supplementary table 5). At a willingness- 
to- pay threshold of £20 000 per QALY, naproxen had an 80% 
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Table 2 Comparison of secondary outcome measures at day 7 and week 4 follow- up
naproxen Colchicine
OR (95% CI)
(p value)*
OR (95% CI)
(p value)†
Complete pain resolution, n (%)
  7 days 115 (67.3) 116 (67.1) 0.96 (0.60 to 1.54)
(p=0.87)
0.95 (0.60 to 1.48)
(p=0.81)
  4 weeks 130 (75.1) 130 (73.4) 0.83 (0.51 to 1.36)
(p=0.46)
0.90 (0.56 to 1.44)
(p=0.66)
Days to complete pain resolution, median (IQR) 5 (day 4, week 4) 6 (day 4, week 4) – –
Patient assessment of global treatment response (completely/much better), n (%)
  7 days 114 (71.3) 110 (72.4) 1.11 (0.67 to 1.84)
(p=0.69)
1.03 (0.62 to 1.70)
(p=0.91)
  4 weeks 140 (80.9) 143 (80.8) 0.88 (0.51 to 1.52) (p=0.64) 0.96 (0.56 to 1.64)(p=0.87)
Recurrence/relapse of gout flare during 4- week follow- up, n (%) 40 (30.1) 54 (35.1) 1.28 (0.78 to 2.13)
(p=0.33)
1.24 (0.77 to 1.99)
(p=0.37)
Consultation/re- attendance for gout during 4- week follow- up, n (%)
  Health professional‡ 30 (22.6) 41 (26.6) 1.43 (0.82 to 2.51)
(p=0.213)
1.39 (0.82 to 2.34)
(p=0.22)
  GP 26 (19.4) 39 (25.3) 1.69 (0.93 to 3.05)
(p=0.083)
1.56 (0.89 to 2.72)
(p=0.12)
   Number of times
    1 14 (58.3) 27 (69.2) – –
    2 8 (33.3) 10 (25.6)
    3 2 (8.3) 2 (5.1)
  Practice nurse 7 (5.3) 10 (6.6) 1.31 (0.47 to 3.64)
(p=0.61)
1.23 (0.45 to 3.32)
(p=0.69)
   Number of times
    1 5 (71.4) 9 (90.0) – –
    2 1 (14.3) 1 (10.0)
    3 1 (14.3) 0 (0.0)
  Emergency GP 6 (4.5) 6 (3.9) 0.84 (0.26 to 2.68)
(p=0.77)
0.87 (0.30 to 2.57)
(p=0.81)
  Emergency department 1 (0.8) 1 (0.7) – 1.23 (0.07 to 21.5)
(p=0.89)
Taken time off work because of gout during 4- week follow- up, n (%) 11 (8.6) 8 (5.3) 0.61 (0.22 to 1.64)
(p=0.33)
0.76 (0.31 to 1.91)
(p=0.57)
  Days, median (IQR) 4 (2, 12) 3 (3, 17) – –
OR for colchicine relative to naproxen.
*Analysis of complete case data (adjusted for baseline pain, age and gender).
†Analysis through multiple imputation via chained equations with logistic (binary/ordinal) regression model (adjusted for age, sex and baseline pain) based on full ITT on 50 
imputations.
‡Health professional: GP, practice nurse, emergency GP and/or accident and emergency.
GP, general practitioner; ITT, intention- to- treat.
chance of being cost- effective compared with colchicine (online 
supplementary figure).
dISCuSSIOn
We found substantial within- group improvements in pain 
intensity in both groups but no statistically significant differ-
ence between naproxen and low- dose colchicine over the first 
7 days. Naproxen appeared to provide faster pain relief, which 
could be explained by the 750 mg loading dose although the 
between- group difference at day 2 was small and possibly 
spurious. Side effects, particularly diarrhoea, and analgesic 
use were more frequent with colchicine. There were no major 
harms with naproxen. Naproxen was slightly more cost- 
effective than colchicine. These findings suggest that naproxen 
should be considered ahead of low- dose colchicine to treat 
gout flares in primary care in the absence of contraindications.
This is the first head- to- head comparison of naproxen 
and colchicine for gout flares and the first randomised trial 
of colchicine at this dose. In an equivalence trial comparing 
naproxen and prednisolone for gout flare,10 mean pain reduc-
tion (0–100 mm visual analogue scale) was 46 mm with 
naproxen by day 4 similar to the 4.1 mean reduction in our 
trial. A reduction of 2 points on a 0–10 pain NRS has been 
shown to be clinically significant in chronic pain.27 Only 70% 
of participants were completely/much better by day 7 and 
80% by week 4, consistent with clinical observations that 
flares often persist beyond 1 week and one- third of partici-
pants reporting a recurrent flare by week 4. There have been 
two placebo- controlled trials of colchicine for gout flare, one 
used a traditional high- dose regime13 whereas the AGREE trial 
included both high- dose and low- dose arms.14 Lower doses 
are recommended to lessen gastrointestinal side effects while 
maintaining effectiveness.3–5 We used the UK recommended 
dose of colchicine, which is intermediate to the regime used 
by Ahern et al and the AGREE trial.13–15 Forty- two per cent 
of participants reported diarrhoea in week 1 compared with 
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Table 3 Use of medication for relief of gout pain over the first week (diary days 1–7) and between weeks 2 and 4 (week 4 follow- up)
days 1–7 Weeks 2–4
naproxen Colchicine OR (95% CI) (p value) naproxen Colchicine OR (95% CI) (p value)
n (%)* n (%)* Complete case* Imputed† n (%)* n (%)* Complete case* Imputed†
Paracetamol 20 (13.4) 34 (23.6) 2.09 (1.11 to 3.93)
(p=0.022)
1.91 (1.05 to 
3.51)
(p=0.035)
10 (7.5) 11 (7.1) 1.12 (0.45 to 2.82)
(p=0.81)
0.98 (0.40 to 2.37)
(p=0.96)
Ibuprofen 16 (10.7) 20 (13.9) 1.54 (0.72 to 3.29)
(p=0.27)
1.58 (0.80 to 
3.12)
(p=0.19)
12 (9.0) 27 (17.5) 2.34 (1.11 to 4.94)
(p=0.026)
1.93 (0.90 to 4.14)
(p=0.089)
Diclofenac 2 (1.3) 4 (2.8) – – 4 (3.0) 6 (3.9) – –
Indomethacin 1 (0.7) 0 (0.0) – – 2 (1.5) 5 (3.2) – –
Tramadol 1 (0.7) 0 (0.0) – – 1 (0.7) 2 (1.3) – –
Codeine 7 (4.7) 21 (14.6) 3.62 (1.47 to 8.93)
(p=0.005)
3.20 (1.35 to 
7.57)
(p=0.008)
12 (9.0) 8 (5.2) 0.60 (0.22 to 1.65)
(p=0.32)
0.59 (0.23 to 1.50)
(p=0.27)
Prednisolone 3 (2.0) 2 (1.4) – – 2 (1.5) 1 (0.6) – –
Any analgesic or non- 
naproxen NSAID‡
37 (24.8) 61 (42.4) 2.23 (1.35 to 3.66)
(p=0.001)
1.89 (1.24 to 
2.88)
(p=0.003)
37 (27.6) 52 (33.8) 1.34 (0.81 to 2.21)
(p=0.26)
0.95 (0.63 to 1.43)
(p=0.81)
OR for colchicine relative to naproxen (adjusted for age, gender and baseline pain score). *Analysis of complete case data (days 1–7: n=288; five cases excluded due to missing 
baseline pain scores; week 4: n=283; five cases excluded due to missing baseline pain scores). †Analysis of imputed data (n=399). n/a: analysis not applicable (as it is an 
evaluation of compliance with allocated treatment). –, ORs not estimated due to small frequency counts.
*Complete response to medication questions: diary days 1–7—149 in naproxen group and 144 in colchicine group; week 4—134 in naproxen group and 154 in colchicine group.
†Imputed data set: 200 in naproxen group; 199 in colchicine group (full ITT analysis).
‡Paracetamol or codeine or tramadol or ibuprofen or diclofenac or indomethacin.
ITT, intention- to- treat; NSAID, non- steroidal anti- inflammatory drug.
100% with the regime of Ahern et al and 77% and 23% in 
the AGREE trial high- dose and low- dose regimes, respectively. 
Eighteen per cent in the naproxen group reported diarrhoea, 
similar to 14% in the placebo group in the AGREE trial. It was 
unexpected that headache differed between the groups, but it 
is plausible that naproxen may have a protective effect to treat 
or prevent headaches. Colchicine is considered to be more 
effective if given in the first 12–36 hours of a flare.4 5 14 Two- 
thirds of our participants initiated medication over 24 hours 
after symptom- onset providing ‘real- world’ evidence that low- 
dose colchicine is effective even when treatment is delayed due 
to patient or service- related factors.
Strengths of this trial include its primary care setting and 
pragmatic design. Although this should ensure generalis-
ability to most patients with gout who are managed in the 
community, we did not assess existing comorbidities, use 
of urate- lowering therapy or prior flare rates to verify this. 
Gout diagnosis was made clinically rather than using validated 
criteria or additional investigations risking misclassification, 
although clinical diagnosis of gout in UK primary care has a 
positive predictive value of 90%.28 Further limitations include 
the open- label design without blinded outcome assessment or 
placebo tablets, and collection of solely self- reported outcomes 
without assessing the effect of NSAIDs on objective measures 
such as blood pressure or renal function. More participants 
in the naproxen group had experienced gout in the past and 
hence probably taken trial medications previously, possibly 
influencing perception of treatment effect, although partici-
pating clinical staff were trained to maintain equipoise. Since 
having recurrent flares increases the likelihood of a correct 
diagnosis,29 misclassification could have been greater in the 
colchicine group. Hence, it is possible that the naproxen group 
could have been advantaged, if previous treatment experiences 
influenced outcome reporting or alternative diagnoses such as 
osteoarthritis or palindromic rheumatism respond better to 
NSAID than colchicine. Finally, recruitment fell one short of 
the target of 400 participants. However, follow- up was better 
than anticipated and exceeded the required number of partici-
pants at the primary end- point.
We chose the dose of naproxen specified for gout flares 
in its marketing authorisation,30 although two times per 
day dosing is not uncommon in clinical practice. A previous 
randomised trial demonstrated equivalence of naproxen 
500 mg two times per day to prednisolone for gout flares.10 
Colchicine treatment was limited to 4 days, consistent with 
UK guidance, which advises a maximum total dose of 6 mg 
per course.15 In contrast, the AGREE trial low- dose arm 
comprised a total dose of 1.8 mg over 2 hours,14 although the 
American College of Rheumatology gout guideline recom-
mended that this can be followed by 600 mcg one time or 
two times per day until flare resolution.4 While the longer 
treatment duration could have biased towards naproxen, 
colchicine was effective within the treatment period and 
there were no statistically significant between- group differ-
ences between days 3 and 7.
NSAIDs and colchicine are not the only drugs used to treat 
gout flares. The American College of Physicians recommends 
corticosteroids as first- line treatment, whereas other guide-
lines advise being guided by comorbidities, contraindications, 
previous response and the pattern of joint involvement.3–5 31 
While randomised trials have compared NSAIDs and pred-
nisolone,10 future research should compare the effectiveness 
and safety of colchicine and corticosteroids, particularly in 
patients with contraindications to NSAIDs. We found little 
difference in pain reduction between naproxen and low- 
dose colchicine, but naproxen was associated with fewer side 
effects, less analgesic use and slightly lower costs, suggesting 
that, in the absence of contraindications, naproxen should 
be used ahead of low- dose colchicine to treat gout flares in 
primary care.
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